Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma

Diagnostic Cytopathology

Volumn 31, Issue 6, 2004, Pages 392-396

  Maruta, Junko ^a   Hashimoto, Hironobu ^a   Yamashita, Hiroto ^a   Yamashita, Hiroyuki ^a   Noguchi, Shiro ^a  

^a Noguchi Thyroid Clin/Hosp Found   (Japan)

Author keywords

Aspiration cytology; CD44v6; Galectin 3; Immunostaining; Thyroid follicular tumor

Indexed keywords

CD44V6 ANTIGEN; GALECTIN 3;

ADENOMA; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; FOLLICULAR CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID TUMOR; TUMOR VOLUME;

ADENOMA; ADULT; ANTIGENS, CD44; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY, FOLLICULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALECTIN 3; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 9644254351     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20156     Document Type: Article

References (24)

1. Chiariotti L, Berlingieri MT, De Rosa P, et al. Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 1992;7:2507-2511.
2. Fernandez PL, Merino MJ, Gomez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997;181:80-86.
3. Gu J, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Expression of splice variant of CD44 in thyroid neoplasms derived from follicular cells. Pathol Int 1998;48:184-190.
4. Cvejic D, Savin S, Panuovic I, Tatic S, Havelka M, Sinadinovic J. Immnohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 1998;18:2637-2641.
5. Orlandi F, Ssggiorato E, Pivano G, et al. Galection-3 is a presugical marker of human thyroid carcinoma. Cancer Res 1998;58:3015-3020.
6. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-2484.
7. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
8. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G. Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 2001;12:275-279.
9. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evolution of thyroid nodules. J Clin Oncol 1999;17:3494-3502.
10. Kawachi K, Matsushita Y, Yonezawa S, et al. Galectih-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000;31:428-433.
11. Bartolazzi A. Improving accuracy of cytology for nodular thyroid lesions. Lancet 2000;355:1661-1662.
12. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
13. Lloyd RV. Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocr Pathol 2001;12:255-257.
14. Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5152-5158.
15. Ermak G, Gerasimov G, Trohina K, et al. Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and non-neoplastic lesions lesions of the human thyroid. Cancer Res 1995;55: 4594-4598.
16. Bohm JP, Niskanen LK, Pirinen RT, et al. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. J Pathol 2000;192:321-327.
17. Martins L, Matsuo SE, Ebina KN, Kulcsar MAV, Friguglietti CUM, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumor. J Clin Endocrinol Metab 2002;87: 4806-4810.
18. Arakake Y, Umeki K, Kiyoyama K, et al. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002;26:366-372.
19. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcil EM, Baloch ZW. Immunohistochemical expression of galection-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
20. Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid 1998;8:377-383.
21. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasms". Mayo Clin Proc 1997;72:913-916.
22. Yamashita H. Evaluation of thyroid nodules. In: Clark OH, Noguchi S, editors. Thyroid cancer: diagnosis and treatment. St. Louis, MO: Quality Medical Publishing, Inc.; 2000. p 21-37.
23. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002;26:41-44.
24. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery 1994; 116:1054-1060.